AZD2962 / AstraZeneca - LARVOL DELTA

D7770C00001: A study of AZD2962, an IRAK4 inhibitor, in Participants with Haematologic Neoplasms (clinicaltrialsregister.eu) - P1/2 | N=7 | Suspended | Sponsor: AstraZeneca AB | Recruiting ➔ Suspended

Monotherapy • Trial suspension • Chronic Myelomonocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers) (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting | Phase classification: P1/2 ➔ P1 | Initiation date: Jul 2025 ➔ Nov 2025

Enrollment open • Monotherapy • Phase classification • Trial initiation date • Hematological Malignancies • Oncology